Here are some highlights of TheraDoc v4.5.2:

-LabID event workflow update

-Updated NHSN definitions

-Updated Surgical Site Infection (SSI) tracking and reporting capabilities

Current TheraDoc users who would like more detailed information on TheraDoc v4.5.2 should reach out to their TheraDoc Regional Business Manager.

P09-0213-0001

TheraDoc Infection Control Assistant scored the highest overall performance rating in KLAS’ Infection Control & Monitoring market segment, demonstrating excellence and leadership in serving customers and meeting their expectations. TheraDoc also received the highest product quality rating in its category, and the highest customer willingness to repurchase the software again (95 percent).[1]

“Hospira is honored that TheraDoc has been recognized for excellence in infection monitoring and surveillance software,” said France Pitera, vice president, Clinical Information Technology, Hospira. “This recognition is very meaningful since it comes as a direct result of feedback from TheraDoc users. This close working relationship with our users is one key reason why 100 percent of the more than 600 hospitals and healthcare facilities nationwide that have acquired TheraDoc still retain the system today.*”

The TheraDoc clinical surveillance system helps infection preventionists tackle many of their most significant challenges, including time spent on regulatory reporting, time to identification of healthcare-associated infections (HAIs), time to isolation of patients with infectious diseases, and tracking of organism resistance.

“After a thorough review of available systems, we chose TheraDoc to support our Infection Prevention program,” says Peggy Thompson, R.N., B.S.N., C.I.C., director of Infection Prevention at Tampa General Hospital. “It has proven to be an invaluable tool in the ever-changing world of infections and regulatory requirements. TheraDoc staff is receptive and incorporates changes based on feedback from their customers.”

The TheraDoc Infection Control Assistant provides infection preventionists with real-time (a matter of seconds) information needed to make a valid identification of infections, while leaving final determination in the hands of infection preventionists. The Infection Control Assistant also delivers powerful tools enabling infection preventionists to configure workflow to their unique needs, develop their own alerts, select from a large library of existing alerts, and automate creation of reports for the National Healthcare Safety Network.

As part of a suite of knowledge modules that make critical patient information and medical knowledge readily available, the Infection Control Assistant is designed to help clinicians intervene quickly, prescribe appropriately, and improve the quality and safety of patient care.[2]^,[3] The TheraDoc Clinical Intelligence™ Platform is the engine that powers these software modules, which also include the Antibiotic Assistant™, ADE Assistant™, Clinical Alerts Assistant™ and Anticoagulation Assistant™. For more information, visit www.theradoc.com.

KLAS is a research firm specializing in monitoring and reporting on the performance of healthcare vendors. KLAS’ mission is to improve delivery by independently measuring vendor performance for the benefit of its healthcare provider partners, consultants, investors, and vendors. Working together with executives from more than 4,500 hospitals and more than 2,500 clinics, KLAS delivers timely reports, trends, and statistics that provide a solid overview of vendor performance in the industry. KLAS measures performance of software, professional services, medical equipment, and infrastructure vendors.

About Hospira

Hospira, Inc., is the world’s leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.

###

[1] “Best in KLAS Awards 2012: Software and Services Report,” December 2012. © 2012 KLAS Enterprises, LLC. All rights reserved. www.KLASresearch.com.

LAKE FOREST, Ill., March 9, 2012 /PRNewswire via COMTEX/ –Hospira (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, today announced that CHRISTUS Health, one of the country’s 10 largest Catholic healthcare systems, has selected Hospira’s TheraDoc™ clinical surveillance system to support its patient safety and infection prevention efforts across 23 hospitals in Arkansas, Louisiana and Texas.

CHRISTUS hospitals will use the Clinical Intelligence™ Platform — which is the engine that powers the TheraDoc system — to collect relevant patient data from multiple hospital information sources including laboratory, pharmacy, radiology and surgery, helping clinicians identify changes in patients’ conditions and alerting them to potential problems that need to be addressed. The Infection Control Assistant™ module will provide automated surveillance and tracking of healthcare-associated infections (HAIs) — a critical healthcare issue that impacts more than 1.7 million patients — an estimated 60 percent of which are caused by a drug-resistant bacteria, in the United States each year.(1,2) The TheraDoc system also will be used to facilitate mandatory reporting requirements such as HAI reporting, as well as a range of other patient safety and quality improvement activities.

According to Brandee Lujan, R.N., infection preventionist at CHRISTUS Health and member of the surveillance software review committee, the TheraDoc system was selected after a rigorous, year-long evaluation process that included several potential vendors. Lujan said CHRISTUS Health needed a solution that could assist in more quickly capturing patient safety trends and allow clinicians to proactively respond in order to support its “culture of safety” — a philosophy aimed at taking the already high-quality care provided by CHRISTUS Health to even higher levels. A further challenge was identifying a system that could support and improve coordination between hospital departments such as infection prevention and pharmacy, as well as a large number of different facilities across many regions.

“We were most impressed with the TheraDoc team — when we asked questions, their responses made it clear that they were proactive and planned ahead,” Lujan said. “They have worked closely with the National Healthcare Safety Network (NHSN) and other agencies to understand what’s coming down the road. When we asked how they were going to address future challenges, their answers were solid, and we could tell that they understood our needs and were capable of meeting them — now and into the future. This proactive approach is exactly what we need in a clinical information technology partner.”

France Pitera, vice president, Clinical Information Technology, Hospira, said the adoption of TheraDoc technology by CHRISTUS Health reflects the critical need for a comprehensive clinical surveillance platform that can help address the fragmentation of medical information in hospitals and the explosion of information fueled by electronic medical record systems.

“Collecting more patient data is only part of the equation,” Pitera said. “Intelligent clinical surveillance systems must transform that information into pertinent, organized clinical knowledge, and deliver it to the right clinicians at the right time. This enables clinicians to take action to improve patient safety and reduce the added costs of treating HAIs and other preventable injuries. We are impressed with CHRISTUS Health’s culture of safety and honored to partner with the organization to further its patient safety and quality initiatives.”

In addition to adopting the Clinical Intelligence Platform and Infection Control Assistant, CHRISTUS Health will evaluate TheraDoc system Pharmacy Solutions tools (ADE Assistant™, Antibiotic Assistant™ and Anticoagulation Assistant™, which are designed to help clinicians optimize drug therapy and avoid preventable medication errors, as well as help increase the efficiency of pharmacists. The Pharmacy Solutions tools will be piloted in several hospitals in the CHRISTUS Spohn Health system in Texas.

About the TheraDoc Clinical Surveillance System
The TheraDoc clinical surveillance system is actively used in almost 400 U.S. hospitals, making critical patient information and medical knowledge readily available to help clinicians intervene quickly, prescribe appropriately, and improve the quality of patient care, as well as facilitate reporting of HAIs via the NHSN. The Clinical Intelligence Platform is the engine that powers several knowledge modules, including the Infection Control Assistant, Antibiotic Assistant, ADE Assistant, Clinical Alerts Assistant™ and Anticoagulation Assistant. For more information, visit www.theradoc.com or call (801) 415-4400.

About Hospira
Hospira, Inc., is the world’s leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.

(1) Klevens R, Edwards J, Richards C, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Reports. 2007;122:160-166.

(2) World Health Organization. Medicines are losing their effectiveness, 1999, Available from: http://www.who.int/infectious-disease-report/pages/ch12text.html, Accessed March 6, 2012.

LAKE FOREST, Ill., June 29, 2011 /PRNewswire via COMTEX/ –

Hospira (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced its support for North Carolina’s new law establishing a statewide surveillance and reporting system for 14 specified healthcare-associated infections (HAIs). The legislation, known as the Model Healthcare-Associated Infections Law, is effective today and institutions have until Dec. 31 to comply with its provisions. It specifies rules for a statewide reporting and surveillance system emphasizing a particular preference for electronic surveillance. The legislation is supported by the North Carolina Hospital Association, the North Carolina Division of Public Health and healthcare facilities throughout the state.

(Logo: http://photos.prnewswire.com/prnh/20040503/HSPLOGO)

“We are pleased to be part of this improvement in infection control and standardized reporting methods for North Carolina,” said Hugh Tilson, senior vice president, North Carolina Hospital Association. “We are confident that this legislation will build on all of the work we are doing to improve the quality of care and reduce infection rates throughout the state.”

These soon-to-be required reporting and surveillance systems help prevent the occurrence of major patient safety hazards like HAIs, adverse drug events and antimicrobial resistant infections. These have been linked to increased morbidity and mortality, and have an enormous financial impact on both healthcare institutions and society at large. For example, an estimated 1.7 million patients develop an HAI in the United States each year, and 99,000 die as a result, adding $28 billion to $33 billion in healthcare costs annually.(1)

The state of Pennsylvania passed a similar law in 2007, with very positive results. After implementing the reporting program for HAIs, which also requires use of electronic clinical surveillance systems to track and report infections, the Pennsylvania Department of Health reported a 12.5 percent reduction in HAIs in the state’s acute-care hospitals in 2009.(2)

In North Carolina, several facilities have preemptively adopted electronic clinical surveillance systems, such as Hospira’s TheraDoc™ platform, which interface with a number of data sources to provide near real-time, actionable information to help identify infections sooner, improve efficiency and workflow and allow clinicians more time for patient interventions, HAI improvements and education.

“We implemented electronic clinical surveillance software in February 2010 and have seen improved efficiency in surveillance and tracking of healthcare-associated infections,” explained Robin Carver, director of infection prevention, WakeMed Health & Hospitals, in Raleigh, North Carolina. “The system has allowed WakeMed clinicians to spend more time on HAI education and prevention and less time on data collection and reporting.”

“This new legislation will help support Hospira’s focus on reducing HAIs and other adverse patient events at healthcare facilities across the United States, helping to improve patient safety, reduce healthcare costs and increase care quality,” added France Pitera, vice president, Clinical Information Technology, Hospira.

About The TheraDoc Clinical Surveillance Platform
TheraDoc systems are actively used in more than 300 U.S. hospitals, making critical patient information and medical knowledge readily available to help clinicians intervene quickly, prescribe appropriately and improve the quality of patient care, as well as facilitate reporting of HAIs via the NHSN. The TheraDoc clinical surveillance platform is the engine that powers several knowledge modules, including the Infection Control Assistant™, Antibiotic Assistant™, ADE Assistant™, Clinical Alerts Assistant™ and Anticoagulation Assistant™. For more information about TheraDoc, visit http://www.theradoc.com or call (801) 415-4400.

About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost, and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at http://www.hospira.com.

(1) U.S. Department of Health & Human Services. (n.d.) HHS Action Plan to Prevent Healthcare-Associated Infections: Coordination, Evaluation, and Conclusion, http://www.hhs.gov/ash/initiatives/hai/cec.html, Accessed June 21, 2011
(2) Ledue, Chelsey. “HAI report highlights improvement at Pennsylvania hospitals.” Healthcare Finance News, June 28, 2010, http://www.healthcarefinancenews.com/news/hai-report-highlights-improvement-pennsylvania-hospitals, Accessed April 16, 2011
SOURCE Hospira

LAKE FOREST, Ill., May 23, 2011 /PRNewswire via COMTEX/ –

Hospira (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced that Hospira and DSS, Inc., are the recipients of an Industry Innovation Award from the U.S. Department of Veterans Affairs (VA) for Hospira’s TheraDoc™ clinical surveillance system. As a result, DSS, Inc., a healthcare information technology provider, will partner with the VA and Hospira to implement the TheraDoc software as a pilot project at several VA medical centers. The pilot is among only one percent of ideas selected from more than 10,000 submitted to date through the VA Innovation Initiative.
The pilot program will focus on using TheraDoc clinical surveillance technology to help identify and decrease the impact of adverse drug events (ADEs). Using DSS technology, the TheraDoc software interfaces with the VA’s proprietary electronic health record to receive the appropriate data to identify, analyze and report ADEs in the TheraDoc system. TheraDoc software is currently in use at seven VA medical centers for a broad range of patient safety applications including: infection control, antimicrobial stewardship and ADE reduction.
Adverse drug events are linked to increased morbidity and mortality, and have a substantial negative impact on healthcare institutions and society. For example, (1)(2)
more than 770,000 people are injured or killed annually in hospitals from ADEs,
ADEs cost as high as $5.6 million per hospital each year, and
ADEs cost up to $5.6 billion annually in the United States.
“Hospira is honored to receive this award and be a part of a program focused on improving patient safety and the quality of care we provide to our veterans,” said France Pitera, vice president, Clinical Information Technology, Hospira. “Through this clinical surveillance system pilot program, these hospitals will have additional tools to support ADE reduction and be able to evaluate technologies that could possibly be implemented across VA medical centers nationwide.”
About the TheraDoc Clinical Surveillance System
The TheraDoc clinical surveillance system is actively used in more than 300 U.S. hospitals, making critical patient information and medical knowledge readily available to help clinicians intervene quickly, prescribe appropriately and improve the quality of patient care, as well as facilitate reporting of healthcare-acquired infections via the National Healthcare Safety Network. The TheraDoc Clinical Intelligence™ platform is the engine that powers several knowledge modules, including the Infection Control Assistant™, Antibiotic Assistant™, ADE Assistant™, Clinical Alerts Assistant™ and Anticoagulation Assistant™. For more information about TheraDoc, visit http://www.theradoc.com or call (801) 415-4400.
About DSS
DSS, Inc. develops and supplies integrated enhancements to the Veterans Affairs VistA system and specializes in healthcare IT solutions that improve quality and productivity. The organization also designs applications that are compatible with the Indian Health Services RPMS and the Department of Defense’s healthcare systems.
vxVistA is DSS’ open source version of VistA that has been enhanced to meet the needs of non-VA users. The company also offers add-on products including behavioral health, clinical decision support, dental electronic records, document imaging and revenue cycle solutions. To foster the adoption of open source in healthcare organizations, DSS is a founder and supporter of a community-driven, collaboration environment Web site, www.vxVistA.org that acts as a forum for discussion and best practices among worldwide vxVistA and VistA EHR users. For more information on DSS, Inc., visit www.dssinc.com.
About Hospira
Hospira, Inc., is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost, and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at http://www.hospira.com.
(1) Agency for Healthcare Research and Quality. March 2001. Reducing and Preventing Adverse Drug Events To Decrease Hospital Costs. Research in Action, Issue 1. http://www.ahrq.gov/qual/aderia/aderia.htm, Accessed May 11, 2011
(2) Bates et al. “The costs of adverse drug events in hospitalized patients.” JAMA. 1997; 277:307-311
SOURCE Hospira

LAKE FOREST, Ill., April 7, 2011 /PRNewswire via COMTEX/ –

As part of World Health Day 2011, the World Health Organization (WHO) is calling on policy makers, providers, the public and the healthcare industry to take action to combat the serious health threat of antimicrobial resistance (AMR). Aligned with these efforts, Hospira, Inc. (NYSE: HSP) is focusing on the growing importance of clinical surveillance systems to help reduce AMR by helping healthcare providers optimize antibiotic therapy and provide the “right drug for the right bug.”
Antimicrobial agents, used to treat infections, are one of the most important advances in medicine, alleviating suffering from infectious diseases and saving countless lives over the past 70 years.(1) According to WHO, the world is at risk of losing this critical arsenal of medicines due to the overuse and misuse of antimicrobials, as well as poor infection-control practices, resulting in the spread of healthcare-associated infections (HAIs). These challenges increase antimicrobial use and resistance, and have been linked to patient morbidity and mortality. According to WHO reports, at any given time, approximately 1.7 million people have an HAI, an estimated 60 percent of which are caused by a drug-resistant bacteria.(2)(3)
In the United States, antimicrobial drug resistance is estimated to deliver an incremental cost of $16.6 billion to $26 billion annually.(4) As a result, hospitals are taking steps to address the problem, utilizing clinical surveillance systems to help them identify and prevent HAIs and combat AMR through real-time decision support focused on improving antibiotic use.
Clinical surveillance systems play a key role in the antimicrobial stewardship program at Henry Ford Hospital in Detroit, part of the Henry Ford Health System, helping to replace inefficient, labor-intensive manual methods of antibiotic and antimicrobial monitoring.
“Henry Ford Hospital deployed the TheraDoc™ clinical surveillance platform to improve the efficiency of the antimicrobial stewardship program,” said Ed Szandzik, R.Ph., M.B.A., director of pharmacy, Henry Ford Health System. “The technology has helped prevent the overuse and misuse of antibiotics. Our stewardship program has been able to reduce antimicrobial use by 20 percent and help reverse the trend on C.difficilerates (which are currently below the Centers for Disease Control benchmark) through enhanced guidelines, policies, procedures and electronic monitoring.”
Policy makers are also taking steps to address the growing problems of HAIs and the potential for associated antimicrobial resistance. For example, U.S. Rep. Jim Matheson (D-Utah) has been a leader in this area with his legislation: “Strategies to Address Antimicrobial Resistance Act” (STAAR Act), which supports many of the WHO AMR policies. In addition, several states have enacted legislation to require statewide reporting of HAIs. Many states now require hospitals to electronically report HAIs through the National Healthcare Safety Network (NHSN).
Reporting HAIs alone, however, is often not enough. Combating AMR requires a comprehensive approach of reducing HAIs through surveillance and the appropriate use of antibiotics. This comprehensive approach is already achieving results in some states. After implementing a mandatory reporting program for HAIs, which also requires use of electronic clinical surveillance systems to track and report infections, the Pennsylvania Department of Health reported a 12.5 percent reduction in HAIs in the state’s acute-care hospitals in 2009.(5)
“Reducing HAIs is critical in the fight against antimicrobial resistance, as poor infection prevention and control can increase the spread of antibiotic-resistant infections,” said France Pitera, vice president, Clinical Information Technology, Hospira. “Hospitalized patients can be reservoirs for resistant microorganisms, and patients who are carriers of resistant microorganisms can spread infections to other patients. For this reason, electronic clinical surveillance systems that leverage real-time data exchange to help hospitals address both problems — HAIs and antimicrobial resistance — are crucial.”
About the TheraDoc Clinical Surveillance Platform
TheraDoc systems are actively used in more than 300 U.S. hospitals, making critical patient information and medical knowledge readily available to help clinicians intervene quickly, prescribe appropriately and improve the quality of patient care, as well as facilitate reporting of HAIs via the NHSN. The patented TheraDoc clinical surveillance platform is the engine that powers several knowledge modules, including the Infection Control Assistant™, Antibiotic Assistant™, ADE Assistant™, Clinical Alerts Assistant™ and Anticoagulation Assistant™. For more information about TheraDoc, visit http://www.theradoc.com or call (801) 415-4400.
About Hospira
Hospira, Inc., is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost, and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at http://www.hospira.com.
(1) Centers for Disease Control and Prevention. July 22, 2010. About Antimicrobial Resistance: A Brief Overview, http://www.cdc.gov/drugresistance/about.html, Accessed April 6, 2011
(2) U.S. Department of Health & Human Services. (n.d.) Healthcare-Associated Infections, http://www.hhs.gov/ash/initiatives/hai/, Accessed March 29, 2011
(3) World Health Organization. Medicines are losing their effectiveness, 1999, http://www.who.int/infectious-disease-report/pages/ch12text.html, Accessed April 6, 2011
(4) Center for Global Development. The Race Against Drug Resistance, 2010, http://www.cgdev.org/files/1424207_file_CGD_DRWG_FINAL.pdf, Accessed April 6, 2011
(5) Ledue, Chelsey. “HAI report highlights improvement at Pennsylvania hospitals.” Healthcare Finance News, June 28, 2010, http://www.healthcarefinancenews.com/news/hai-report-highlights-improvement-pennsylvania-hospitals, Accessed April 16, 2011
SOURCE Hospira

LAKE FOREST, Ill., April 1, 2011 /PRNewswire via COMTEX/ –
Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced the launch of its enhanced TheraDoc™ clinical surveillance system, used by hospitals to help improve patient safety and prevent adverse events such as healthcare-associated infections (HAIs). The enhanced TheraDoc system includes new features and functionalities designed to improve user satisfaction, reporting capabilities and work efficiency.
(Logo: http://photos.prnewswire.com/prnh/20040503/HSPLOGO)
Patient safety issues such as HAIs, adverse drug events and antimicrobial resistant infections have been linked to increased morbidity and mortality, and have an enormous financial impact on healthcare institutions and society. An estimated 1.7 million patients develop an HAI in the United States each year, and 99,000 die as a result, adding $28-$33 billion in healthcare costs.(1)
The TheraDoc platform enhancements are designed to help hospitals meet and improve upon evolving quality metrics and national patient safety goals. The new platform also helps clinicians more easily identify antimicrobial resistant pathogens and drug-bug mismatches. Improvements to the TheraDoc Infection Control Assistant™ module facilitate seamless electronic reporting of HAIs to the National Healthcare Safety Network (NHSN) and provide a new infection control dashboard for enhanced reporting, data comparison and benchmarking. Clinicians and healthcare institutions can now use TheraDoc to automatically track and generate electronic reports regarding urinary tract infections (UTI), central line insertion practices (CLIP), laboratory-identified multi-drug resistant organisms (MDRO) and C. difficile-associated disease (CDAD) events. This additional functionality will help to decrease manual sorting of laboratory results and streamline public health reporting.
“The enhanced TheraDoc platform has added even more valuable tools available to our infection prevention team at Kootenai Health,” said Lee Rieken R.N., C.I.C., infection prevention unit supervisor, Kootenai Health in Idaho. “The TheraDoc team continues to reach out to its customers and listen to their needs. As increasing demands are placed on the infection preventionist, the tools afforded them are increasing as well. I appreciate the dashboard within the new TheraDoc platform, because it is quite intuitive to use and helps us benchmark against NHSN.”
Stanley Pestotnik, M.S., R.Ph., general manager, TheraDoc, Hospira, said, “The enhanced TheraDoc system reflects Hospira’s commitment to delivering innovative patient safety surveillance and clinical-decision support solutions.”
“TheraDoc systems are actively used in more than 300 U.S. hospitals, making critical patient information and medical knowledge readily available to help clinicians intervene quickly, prescribe appropriately and improve the quality of patient care,” Pestotnik said. “The enhancements to our platform will further maximize these important benefits.”
The TheraDoc clinical surveillance platform is being demonstrated at Society for Healthcare Epidemiology of America (SHEA) booth #107 through April 4. For more information about TheraDoc, visit http://www.theradoc.com or call (801) 415-4400.
About Hospira
Hospira, Inc., is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost, and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at http://www.hospira.com.
Private Securities Litigation Reform Act of 1995 –
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the enhanced TheraDoc system. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological and other factors that may affect Hospira’s operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Hospira’s latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.
(1) U.S. Department of Health & Human Services. (n.d.) Healthcare-Associated Infections, http://www.hhs.gov/ash/initiatives/hai/ Accessed March 29, 2011
SOURCE Hospira

We are very proud of the impact we have brought over the past decade to reduce the fragmentation and isolation that exists between patient data and best practice guidelines. Give us a call today to arrange a demo at your facility. We look forward to showing you how TheraDoc can help further your own patient safety initiatives.

(801) 415-4400

LAKE FOREST, Ill., July 13, 2010 /PRNewswire via COMTEX/ –

Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced a study showing how the TheraDoc™ clinical surveillance system helped clinicians at Memorial Hospital Miramar reduce catheter-related infections, which correlated with an increase in infection-control interventions. The hospital, which used TheraDoc to electronically track the number of interventions and catheters removed, as well as infection rates, is reporting the results in a poster presentation at the 2010 Association for Professionals in Infection Control and Epidemiology (APIC) annual conference in New Orleans July 11-15.

Memorial Hospital Miramar, a 178-bed facility in South Florida, began using the TheraDoc Infection Control Assistant™ in 2008 to electronically record requests to remove urinary and central line catheters, and to document catheter-related urinary tract and bloodstream infections. Intervention requests were made by the hospital’s infection preventionist, who attended daily rounds with the medical teams and often suggested the removal of urinary and central line catheters to help reduce infection risk. Months with more interventions were associated with fewer catheter-related infections, providing data to support infection-prevention efforts.

Catheter-associated infections are a significant problem for hospitals. Urinary tract infections (UTIs) account for 40 percent of the healthcare-acquired infections (HAIs) in the United States,(1) and 250,000 to 500,000 catheter-associated bloodstream infections (CABIs) occur in the nation each year. In addition to improving patient safety, avoiding these infections can result in significant cost savings for hospitals — costs for each UTI and CABI are estimated at $600 and up to $29,000, respectively.(2)

According to Alex Chavez, C.I.C., infection-control practitioner at Memorial Hospital Miramar, preventing catheter-related infections is a focus for infection preventionists, but manually documenting and assessing the impact of interventions on infection rates can be challenging. When Chavez learned that the hospital was using TheraDoc to assess pharmacy interventions, he realized that the technology could do the same for infection prevention.

“The ability to electronically document interventions and then tie them to reduced infection rates is critical,” Chavez said. “TheraDoc helps us quantify the value of infection preventionists in improving patient care and demonstrates the importance of interactions between infection preventionists and clinical staff.”

Memorial Hospital Miramar, part of Memorial Healthcare System, has been using TheraDoc for infection prevention since 2008. TheraDoc automates the collection and analysis of clinical data from a range of sources within the hospital and alerts caregivers to clinically significant changes in patients’ conditions that need to be addressed. The software also helps coordinate communication among care teams and hospital executives, and facilitates reporting to public health officials and quality organizations.

“Memorial Healthcare’s innovative use of the TheraDoc clinical surveillance platform spans many areas of patient care — from documenting infection prevention and pharmacy activities and meeting pediatric asthma core quality measures, to tracking H1N1 influenza cases,” said Stanley Pestotnik, M.S., R.Ph., general manager, TheraDoc. “Its success with these initiatives illustrates the versatility of the TheraDoc platform to help clinicians quickly address quality and patient safety challenges that hospitals face every day.”

Other abstracts related to TheraDoc being presented at the 2010 APIC meeting include:

• Can Automated Surveillance Software Assist with Cohorting Patients with Multidrug-Resistant Organisms? Poster #12-128, Hahnamann University Hospital.
• Does an Automated Infection Surveillance System Benefit a Hospital with Limited Information System Resources? Poster #12-131, Hahnamann University Hospital.

With the patented TheraDoc Expert System Platform™ as the engine, the Infection Control Assistant complements several hospital surveillance modules powered by TheraDoc, including the ADE Assistant™, Clinical Alerts Assistant™, Antibiotic Assistant™ and the company’s newest TheraDoc module, the Anticoagulation Assistant™. With 1.7 million HAIs occurring annually, clinicians at the Johns Hopkins Medical Institutions used Infection Control Assistant to help reduce HAI-confirmation time by 50 percent while achieving 98 percent accuracy of infection identification.(3),(4) For more information about the TheraDoc platform, visit http://www.theradoc.com/.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at http://www.hospira.com/default.aspx.

(1) Johnson J, Kuskowski M, Wilt T. Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients. Ann Intern Med. Jan. 17 2006;144:116-126.

(2) Weinstein R. An evidence-based approach to the prevention of central line-associated bloodstream infections in hospitalized patients. http://cme.medscape.com/viewarticle/705882. Accessed May 19, 2010.

(3) Klevens RM, Edwards JR, et. al. Estimating health care-associated infections and deaths in U.S. hospitals. Public Health Reports: Volume 122, March-April 2007. http://www.cdc.gov/ncidod/dhqp/pdf/Scott_CostPaper.pdf Accessed Nov. 4, 2009.

(4) Xiaoyan S, Mackie K, et. al. Benefits of using TheraDoc to assist in surveillance for central line associated nomsocomial bloodstream Infections (CA-BSIs). 17th Annual Scientific Session. SHEA, 2006.

Although anticoagulation therapy is widely used to effectively treat many conditions, adverse events frequently occur due to dosing complexities and difficulties monitoring the safety and efficacy of the medication. Anticoagulants are associated with approximately nine percent of all hospital adverse drug events (ADEs).(1) With 117,700 ADEs each year related to anticoagulant therapy, these types of medication errors represent an annual financial burden of up to $1 billion on the healthcare system.(1,2)

The Anticoagulation Assistant module helps clinicians prevent patient harm by tracking the condition of patients receiving anticoagulation therapy and providing early indications of potential therapeutic concerns or ADEs. Effective monitoring of anticoagulants is essential, with 6.2 percent of patients impacted by an anticoagulant medication error requiring medical intervention and 1.5 percent needing prolonged hospitalization.(3)

The launch of the Anticoagulation Assistant module follows the introduction of an Anticoagulation Alerts package in 2009. Designed for use with the TheraDoc Expert System Platform™ core technology, the Anticoagulation Assistant provides an expanded set of alerts, clinical case dashboards, intervention documentation and a patient flag model for tracking therapy based on Joint Commission standards. The Joint Commission National Patient Safety Goal Accreditation Program indicates that hospitals use standardized practices for anticoagulation therapy and evaluate practices to help reduce the risk of ADEs associated with anticoagulants.(4) The Anticoagulation Assistant supports these important practices, helping to streamline caregiver communication, improve clinical workflow and enhance patient safety.

Pharmacists and clinicians at the University of Pittsburgh Medical Center (UPMC) are using Hospira’s TheraDoc Anticoagulation Assistant software to capture pertinent data and send anticoagulation-related alerts to staff to help prevent patient injury and document compliance with the National Patient Safety Goal.

“The TheraDoc platform has become the backbone of our anticoagulation program to help us quickly catch and document potential adverse events, tests that need to be ordered, or lab values that are too high or too low,” said Sue Skledar, R.Ph., M.P.H., F.A.S.H.P., director of the Drug Use and Disease State Management Program at UPMC. “It’s quick and efficient, and it can be set up to let you know immediately when something needs to be addressed. Rather than looking at five or six reports, TheraDoc provides a single, integrated system for alerting us if we need to take action.”

According to Stanley Pestotnik, M.S., R.Ph., general manager, TheraDoc, Hospira, the Anticoagulation Assistant exemplifies the role the TheraDoc platform plays in helping clinicians address patient safety and medication error prevention with clinical information technology.

“Hospira’s TheraDoc system takes data from a range of sources within the hospital and turns it into actionable information, alerting caregivers to clinically significant events to help them make appropriate — and timely — interventions,” Pestotnik said. “Our platform approach allows healthcare providers to address a variety of patient care issues, ranging from Joint Commission patient safety goals to unanticipated challenges such as the H1N1 influenza outbreak.”

With Hospira’s patented TheraDoc Expert System Platform as the engine, the Anticoagulation Assistant complements several hospital surveillance modules already powered by TheraDoc, including the ADE Assistant™, Clinical Alerts Assistant™, Antibiotic Assistant™ and the company’s leading TheraDoc module, Infection Control Assistant?. With 1.7 million hospital acquired infections (HAIs) occurring annually, Johns Hopkins used Infection Control Assistant to help reduce HAI confirmation time by 50 percent while achieving 98 percent accuracy of infection identification. For more information about the TheraDoc platform, visit www.theradoc.com.

About Hospira Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at www.hospira.com.

Media
Barbara Sullivan
Sullivan & Associates
(714) 374-6174

Tareta Adams
Hospira
(224) 212-2535

Financial Community
Karen King Hospira
(224) 212-2711

Ruth Venning
Hospira
(224) 212-2774

About TheraDoc
TheraDoc is a clinical informatics company dedicated to improving the quality, efficiency and safety of patient care through enhanced clinical decision making. It provides innovative, best-in-class solutions that improve clinical and financial outcomes at a range of provider and payer organizations, including some of the most-respected healthcare institutions in the country. With clinical transparency, TheraDoc’s technologies seamlessly place mission-critical knowledge at the clinician’s fingertips, helping them to confidently manage multiple processes of care across multiple conditions and diseases. The company’s strict adherence to medical informatics standards enables connectivity and interoperability with any hospital’s disparate health information systems.

Founded in 1999, TheraDoc designs, develops and supports a suite of clinical decisions support technologies utilizing inference engines that enable its real-time solutions. TheraDoc’s founders and core medical informatics team are internationally recognized for their pioneering and continuing work in medical expert systems. Their experience in clinical decision support design and development spans two decades. On the Net: www.theradoc.com.

Elixhauser A. and Owens P. (AHRQ). Adverse Drug Events in U.S.
Hospitals, 2004. HCUP Statistical Brief #29. April 2007.
Agency for Healthcare Research and Quality, Rockville, MD.

http://www.hcup-us.ahrq.gov/reports/statbriefs/sb29.pdf

1 Accessed Dec. 30, 2009.
Aspden P, Wolcott J, Bootman J, Cronenwett L, eds. Preventing
Medical Errors: Quality Chasm Series. Washington DC: National
2 Academies Press; 2007. Accessed May 15, 2009.
Fanikos J, Stapinski C, Koo S, Kucher N, Tsilimingras K,
Goldhaber SZ. Medication errors associated with anticoagulant
3 therapy in a hospital. Am J Cardiol.2004; 94(4):532-5.
The Joint Commission. Accreditation Program: Hospitals
National Patient Safety Goals (pre-publication copy). 2009.
The Joint Commission on Accreditation of Healthcare
Organizations. http://www.jointcommission.org/NR/
rdonlyres/868C9E07-037F-433D-8858-0D5FAA4322F2/0/
4 RevisedChapter_HAP_NPSG_20090924.pdf Accessed Feb. 22, 2010.
Klevens RM, Edwards JR, et. al. Estimating health care-
associated infections and deaths in U.S. hospitals. Public
Health Reports: Volume 122, March-April 2007. http://
www.cdc.gov/ncidod/dhqp/pdf/Scott_CostPaper.pdf Accessed
5 Nov. 4, 2009
Xiaoyan S, Mackie K, et. al. Benefits of using TheraDoc to
assist in surveillance for central line associated
nomsocomial bloodstream Infections (CA-BSIs). 17th Annual
6 Scientific Session. SHEA, 2006.

Introduced in October 2009 by HIMSS and the American Society for Quality (ASQ), the Stories of Success! program called for case studies showcasing real-world examples of leveraging health information technology to improve patient safety, quality, effectiveness and efficiency. Memorial Healthcare System was honored by a peer-review body of experts from HIMSS, the Joint Commission, the National Committee for Quality Assurance and the ASQ.

The recognized case study highlighted how MHS’ Joe DiMaggio Children’s Hospital (JDCH) met Children’s asthma care core measures by using a team approach and tools from the TheraDoc computerized safety surveillance and decision support system. Healthcare providers at JDCH found that it was difficult to track all pediatric asthma patients to ensure compliance with the measures. In some cases, patient length of stay was only one to two days, further complicating efforts to comply with the core measures. The team utilized TheraDoc computer-generated alerts to identify pediatric asthma patients based on prescription medication and admissions data as a first step in implementing a core measure for providing pediatric asthma home management care plans to patients and caregivers — resulting in a 97 percent compliance rate with the asthma core measures.

JDCH has used the TheraDoc decision support technology since 2007 for infection prevention, medication safety and other applications. The system automates the collection and analysis of clinical data from a range of sources within the hospital and alerts caregivers to clinically significant information so that appropriate interventions can be made. The software also helps coordinate communication among patient care teams and hospital executives, and facilitates reporting to public health officials and quality organizations.

“We adopted the pediatric asthma initiatives based on our desire to be at the forefront of quality patient care,” said Alice Chan, R.Ph., IT clinical applications manager at MHS. “We were committed to decreasing the need for readmission and achieving a high compliance rate with the quality measures, and TheraDoc helped us streamline the process. We are pleased that we can share our experience and success of using information technology to help improve the quality of patient care.”

According to Stanley Pestotnik, M.S., R.Ph., general manager, TheraDoc, Hospira, JDCH’s success with these quality initiatives illustrates the versatility of the TheraDoc clinical surveillance platform, which provides tools to quickly address a range of quality and patient safety challenges that arise in healthcare every day.

“We are pleased that Joe DiMaggio Children’s Hospital’s outstanding accomplishments were recognized by HIMSS,” Pestotnik said. “Healthcare quality and patient safety challenges continue to be two of the country’s most critical healthcare priorities, and we share the hospital’s ongoing commitment to improving patient safety and care through the management of medical information.”

About the HIMSS “Stories of Success!” Program
The HIMSS “Stories of Success!” are designed to highlight the fulfillment of national priorities established by the National Priorities Partnership and The Joint Commission’s National Patient Safety Goals. Sixteen real-world and peer-reviewed case study submissions were designated as either Tier 1 or Tier 2 finalists as part of the inaugural call for case studies. Memorial Healthcare System was honored in the Tier 2 category. To receive a copy of the case study, e-mail bsullivan@sullivanpr.com.

About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness?. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at www.hospira.com.

Media
Barbara Sullivan
(714) 374-6174
bsullivan@sullivanpr.com

Tareta Adams
(224) 212-2535

Financial Community
Karen King
(224) 212-2711

Ruth Venning
(224) 212-2774

About TheraDoc
TheraDoc is a clinical informatics company dedicated to improving the quality, efficiency and safety of patient care through enhanced clinical decision making. It provides innovative, best-in-class solutions that improve clinical and financial outcomes at a range of provider and payer organizations, including some of the most-respected healthcare institutions in the country. With clinical transparency, TheraDoc’s technologies seamlessly place mission-critical knowledge at the clinician’s fingertips, helping them to confidently manage multiple processes of care across multiple conditions and diseases. The company’s strict adherence to medical informatics standards enables connectivity and interoperability with any hospital’s disparate health information systems.

Founded in 1999, TheraDoc designs, develops and supports a suite of clinical decisions support technologies utilizing inference engines that enable its real-time solutions. TheraDoc’s founders and core medical informatics team are internationally recognized for their pioneering and continuing work in medical expert systems. Their experience in clinical decision support design and development spans two decades. On the Net: www.theradoc.com.

LAKE FOREST, ILLINOIS, December 2, 2009 – Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, announced today that it has acquired Salt Lake City-based TheraDoc, a clinical informatics company that develops hospital surveillance systems. TheraDoc’s two leading products, Infection Control AssistantTM and Antibiotic AssistantTM, join Hospira’s expanding portfolio of medication safety and infection management products. Hospira will demonstrate both products at the Institute for Healthcare Improvement (IHI) 21st Annual National Forum on Quality Improvement in Health Care (Dec. 6 – 9 in Orlando) and the American Society of Health-System Pharmacists (ASHP) Mid-Year Clinical Meeting and Exhibition (Dec. 6 – 10 in Las Vegas).

“The acquisition of TheraDoc aligns well with Hospira’s focus on improving the clinical outcomes, caregiver productivity and safety of patient care,” said Philip Settimi, M.D., vice president, Global Marketing, Devices, Hospira. “TheraDoc is the gold-standard in enterprise-wide clinical surveillance and decision support. Hospira now offers a truly comprehensive solution for medication safety and infection management, which are two of providers’ most pressing healthcare challenges.”

According to the Centers for Disease Control, there are 99,000 deaths due to hospital-acquired infections (HAI) and 1.7 million HAIs annually. Careful monitoring of infections is critical with the Centers for Medicare & Medicaid Services’ emphasis on avoiding “Never Events,” and hospitals facing reduced funding and coverage based on infection rates.

With HAIs costing between $28.4 billion and $33 billion each year, Johns Hopkins used TheraDoc to help reduce HAI confirmation time by 50 percent while achieving 98 percent accuracy of infection identification. TheraDoc’s Infection Control Assistant provides continuous infection monitoring, intelligent alerts and timely analysis of hospital infections. The product joins Hospira’s portfolio of infection management tools, including the LifeShieldTM TKOTM and Antimicrobial CLAVETM, devices that are designed to help address potential infection-related contamination.

In the early stages of the H1N1 influenza pandemic, several hospitals employed TheraDoc’s surveillance platform to more effectively manage their responses. Computerized surveillance helps hospitals manage and coordinate infectious disease care — especially important during fast-moving situations.

“During the recent H1N1 outbreak, TheraDoc was particularly helpful with tracking patient information and monitoring which patients were being admitted with influenza-like symptoms,” said Lori Goffinet, R.N., B.S.N., Infection Prevention & Control, OSF Saint Francis Medical Center in Peoria, Ill.

A key advantage of the TheraDoc technology for OSF and other multi-hospital systems is the ability to access information about infections across all facilities from one central location. As a result, TheraDoc provides a system-wide picture of what is happening with infections.

TheraDoc’s Antibiotic Assistant provides real-time point-of-care screening to arm clinicians with timely and relevant information about antimicrobial resistance trends. This allows clinicians to effectively monitor and analyze the spread of infectious diseases so that the right antibiotic treatment can be prescribed. Antibiotic Assistant complements Hospira’s medication safety products like SymbiqTM and Plum A+TM smart infusion pumps and Hospira MedNetTM safety software, which were also designed to support safe and effective drug delivery.

“Hospira and TheraDoc share a dedication to advancing the quality and safety of care through advanced medical technology,” said Stanley L. Pestotnik, M.S., R.Ph., co-founder, president and CEO, TheraDoc. “TheraDoc’s leadership in providing real-time clinical decision support, combined with Hospira’s market-leading position driving medication safety and infection management, will result in expanded access to technologies that are integral to patient care.”

TheraDoc has approximately 85 employees and prominent customers across the United States, including Johns Hopkins, University of Pittsburgh Medical Center (UPMC), the Mayo Clinic Jacksonville, Northwestern Memorial Hospital, National Institutes of Health Clinical Centers, Yale-New Haven Hospital, Cedars-Sinai Medical System and many more. The company’s products are also under evaluation by hospitals in Canada, the United Kingdom and Australia.

As part of the agreement, Hospira acquired additional assets related to the TheraDoc business, including the headquarters in Salt Lake City, and the TheraDoc employees are now a part of Hospira. Financial details of the agreement were not disclosed.

About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

About TheraDoc
TheraDoc is a clinical informatics leader dedicated to improving the quality, safety, and efficiency of patient care through enhanced clinical decision making. With TheraDoc’s Expert System Platform as the “engine,” the company offers a suite of Knowledge Modules that includes the Infection Control Assistant and Antibiotic Assistant. TheraDoc’s founders and core medical informatics team are internationally recognized for their pioneering and continuing work in clinical decision support design and development, which spans more than two decades. For more information, visit www.theradoc.com.

Media
Tareta Adams
(224) 212-2535

Financial Community
Karen King
(224) 212-2711

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira’s operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Hospira’s latest Annual Report on Form 10-K, and Hospira’s subsequent Quarterly Reports on Form 10-Q, which are filed with the Securities and Exchange Commission, and incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

1 Klevens RM, Edwards JR, et. al. Estimating health care-associated infections and deaths in U.S. hospitals. Public Health Reports: Volume 122, March?April 2007. http://www.cdc.gov/ncidod/dhqp/pdf/Scott_CostPaper.pdf Accessed Nov. 4, 2009
2 Scott RD. Healthcare-associated infections in U.S. hospitals and the benefits of prevention. Economist Division of Healthcare Quality Promotion National Center for Preparedness, Detection, and Control of Infectious Diseases Coordinating Center for Infectious Diseases Centers for Disease Control and Prevention: http://www.cdc.gov/ncidod/dhqp/pdf/hicpac/infections_deaths.pdf. March 2009 Accessed Nov. 4, 2009
3 Xiaoyan S, Mackie K, et. al. Benefits of using TheraDoc to assist in surveillance for central line associated nomsocomial bloodstream Infections (CA-BSIs). 17th Annual Scientific Session. SHEA, 2006

About TheraDoc
TheraDoc is a clinical informatics company dedicated to improving the quality, efficiency and safety of patient care through enhanced clinical decision making. It provides innovative, best-in-class solutions that improve clinical and financial outcomes at a range of provider and payer organizations, including some of the most-respected healthcare institutions in the country. With clinical transparency, TheraDoc’s technologies seamlessly place mission-critical knowledge at the clinician’s fingertips, helping them to confidently manage multiple processes of care across multiple conditions and diseases. The company’s strict adherence to medical informatics standards enables connectivity and interoperability with any hospital’s disparate health information systems.

Founded in 1999, TheraDoc designs, develops and supports a suite of clinical decisions support technologies utilizing inference engines that enable its real-time solutions. TheraDoc’s founders and core medical informatics team are internationally recognized for their pioneering and continuing work in medical expert systems. Their experience in clinical decision support design and development spans two decades. On the Net: www.theradoc.com.